Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Healthcare
/
Dr. Lal PathLabs
LALPATHLAB
Dr. Lal PathLabs
Expanding Middle Class And Digital Health Will Boost Diagnostics
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 25 Analysts
Published
25 Jul 25
Updated
08 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
₹4,020.00
16.7% undervalued
intrinsic discount
08 Aug
₹3,347.80
Loading
1Y
4.4%
7D
4.2%
Author's Valuation
₹4.0k
16.7% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
₹4.0k
16.7% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
37b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹37.2b
Earnings ₹7.7b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
10.64%
Healthcare Services revenue growth rate
0.28%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹7.68b
Earnings '28
x
63.01x
PE Ratio '28
=
₹483.73b
Market Cap '28
₹483.73b
Market Cap '28
/
83.93m
No. shares '28
=
₹5.76k
Share Price '28
₹5.76k
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹4.02k
Fair Value '25